EDIT – editas medicine, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

EDIT

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

11/6

01:02 pm

edit

Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.

Low Report

Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.

Report

11/6

01:02 pm

edit

Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.

Low Report

Editas Medicine, Inc. (NASDAQ: EDIT) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating.

Report

11/5

05:34 pm

edit

Editas Medicine, Inc. (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.

Medium Report

Editas Medicine, Inc. (NASDAQ: EDIT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $12.00 price target on the stock.

Report

11/5

05:22 pm

edit

Rating for EDIT

Medium Report

Rating for EDIT

Report

11/5

11:32 am

edit

Rating for EDIT

Low Report

Rating for EDIT

Report

11/5

11:32 am

edit

Rating for EDIT

Low Report

Rating for EDIT

Report

11/5

10:55 am

edit

Rating for EDIT

Low Report

Rating for EDIT

Report

11/5

10:22 am

edit

Rating for EDIT

Medium Report

Rating for EDIT

Report

11/5

10:22 am

edit

Rating for EDIT

Medium Report

Rating for EDIT

Report

11/5

09:23 am

edit

Rating for EDIT

Medium Report

Rating for EDIT

Report

11/5

09:23 am

edit

Rating for EDIT

Medium Report

Rating for EDIT

Report

11/4

01:15 pm

edit

Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.

Low Report

Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.

Report

11/4

01:15 pm

edit

Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.

Low Report

Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.

Report

10/23

11:08 am

edit

Rating for EDIT

Low Report

Rating for EDIT

Report

10/23

10:19 am

edit

Rating for EDIT

Low Report

Rating for EDIT

Report

10/23

10:19 am

edit

Rating for EDIT

Low Report

Rating for EDIT

Report

10/22

06:03 pm

edit

Rating for EDIT

Low Report

Rating for EDIT

Report

9/19

09:21 am

edit

Editas Medicine, Inc. (NASDAQ: EDIT) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $8.00 price target on the stock.

Low Report

Editas Medicine, Inc. (NASDAQ: EDIT) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $8.00 price target on the stock.

Report

9/19

09:21 am

edit

Editas Medicine, Inc. (NASDAQ: EDIT) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $8.00 price target on the stock.

Low Report

Editas Medicine, Inc. (NASDAQ: EDIT) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $8.00 price target on the stock.

Report

9/19

09:12 am

edit

Rating for EDIT

Medium Report

Rating for EDIT

Report

9/19

09:12 am

edit

Rating for EDIT

Medium Report

Rating for EDIT

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.